Educational & Research Use Only. Not medical advice. Compounds are research-grade and not FDA-approved unless explicitly noted.
02
Section 02 · 4 compounds

Repair, Regeneration & Structural Recovery

Peptides studied for tissue, vascular and skin repair, with the evidence graded honestly.

Home/ Sections/ Repair, Regeneration & Structural Recovery

Tissue repair depends on blood supply, cell migration and orderly rebuilding of collagen. The peptides in this section are studied for their effects on those steps. Most of the evidence is from animal and cell research, and human data are limited, so read each grade carefully.

Each entry opens with an evidence grade, then covers how the compound works, what human, animal and cell studies show, safety, open questions and regulatory status, with numbered references. Grades in this section: B: 1 · C: 1 · D: 1 · E: 1.

C
Evidence grade C · Limited humanWhat this means

Extensive rodent research, but human data are limited to a retrospective chart review, tiny uncontrolled reports, and early trials that were never fully published[1,9].

A synthetic 15-amino-acid peptide with a large body of rat research on tissue and blood-vessel repair, most of it from a single research group, and almost no controlled human data.

Overview

BPC-157 ("Body Protection Compound-157") is a short synthetic peptide that its developers describe as a fragment of a protective protein found in human gastric juice. It was first described in 1993, and since then it has been tested in a long list of rodent injury models: tendons, ligaments, muscle, gut lining and blood vessels[2].

That breadth is what makes it so widely discussed, and also what calls for care. Most of the foundational research comes from one group in Zagreb, Croatia, and independent replication is thin. A 2025 systematic review of its orthopedic use found 35 preclinical studies and only one human study[1]. No long-term human safety data exist.

The site foreman who calls in more trucksPicture a construction site after a storm. BPC-157 seems to act less like new building material and more like a foreman who gets more delivery trucks on the road (new blood vessels) and hands the repair crews (fibroblasts) better maps so they reach the damage faster. Whether that foreman works the same way in people, and whether he might also wave trucks toward places that shouldn't be growing, is still unknown.

Mechanism of Action

Most mechanistic work points to blood-vessel growth (angiogenesis) and nitric oxide signaling. In human vascular endothelial cells, BPC-157 increased VEGFR2, the main receptor for vascular growth signals, and activated the downstream VEGFR2-Akt-eNOS pathway that produces nitric oxide. Blocking receptor internalization cancelled the effect, which suggests that step is part of how it works. In rats with restricted blood flow to a hind limb, it sped recovery of blood flow and increased vessel density[6].

A second line of work from a Taiwanese group looked at tendon fibroblasts, the cells that rebuild tendon. BPC-157 did not make these cells divide faster, but it improved their survival under oxidative stress and increased their migration by activating FAK and paxillin, the proteins cells use to grip and crawl[4]. The same group found it raised growth hormone receptor expression in these cells roughly sevenfold by day 3, making them more responsive to growth hormone[5]. No receptor that BPC-157 binds directly has been identified.

What the Research Shows

Human studies
  • Systematic review, HSS Journal 2025: of 544 records screened (1993 to 2024), 36 studies qualified: 35 preclinical and 1 clinical. The authors rated the overall evidence as low level (IV/V) and found no human safety data[1].
  • Retrospective chart review, knee pain (2021): 16 patients at a single clinic, no control group, outcomes collected by phone. 11 of 12 receiving BPC-157 alone reported less pain. Without a comparison group, placebo and natural recovery cannot be ruled out[3].
  • Ulcerative colitis and Phase I trials: an enema trial in ulcerative colitis and a Phase I study in healthy volunteers exist only as meeting abstracts. A registered oral Phase I trial was cancelled without posting results. The FDA judged this evidence inadequate to support efficacy or safety[9].
Animal studies
  • Rat Achilles tendon transection (Zagreb group, 2003): improved biomechanical, functional and microscopic healing over 14 days compared with saline[7].
  • Rat Achilles transection and repair (independent Turkish group, 2026; n=32): load-to-failure was higher with BPC-157, but the difference was not statistically significant, and histology scores were not significantly better with BPC-157 alone. TB-500 alone did reach significance[8].
  • Rat hind-limb ischemia: faster blood-flow recovery and greater vessel density[6].
  • Rat and dog 28-day toxicology: changes in clotting times and liver-related lab values. Genotoxicity tests were negative[9].
Cell & mechanistic
  • Rat tendon fibroblasts: better survival and migration through FAK-paxillin activation, with no direct effect on proliferation[4]; growth hormone receptor up about sevenfold[5].
  • Human endothelial cells: VEGFR2 upregulation and VEGFR2-Akt-eNOS activation[6].
What This Could Mean in Practice

For now, BPC-157 is a research compound with interesting animal and cell signals around tendon and blood-vessel repair. It is not a proven treatment. The one independent tendon study we found did not reproduce a statistically significant benefit for BPC-157 alone[8], and the human reports are too small and uncontrolled to separate a real effect from placebo or natural healing. Claims of faster recovery rest mainly on rat studies from one group. It is banned in tested sport[13].

Safety & Side Effects
  • Small human reports describe no adverse events, but they had very few participants, short follow-up and unclear monitoring[3,9].
  • No long-term human safety or carcinogenicity data exist. Because BPC-157 promotes blood-vessel growth, reviewers flag a theoretical risk that it could feed undiagnosed tumors. This concern is untested, not demonstrated[2,9].
  • The FDA identified a possible immunogenicity risk (an immune reaction to the peptide or its impurities) for injected or nasal use. No immunogenicity studies have been done[9,10].
  • Animal toxicology found clotting-time and liver-enzyme changes in rats and dogs[9].
  • Product quality is a separate risk: the FDA found no official quality standard (USP monograph) and incomplete impurity, endotoxin and aggregate testing in the material it reviewed[9].

Open Questions

  • Most of the animal research comes from one group, and the one independent tendon replication we found was largely negative for BPC-157 alone[1,8].
  • The "gastric juice protein" it is said to come from has been described mainly by the original group[2].
  • Human trials that were started have gone unpublished or exist only as abstracts, which raises the possibility of publication bias[9].
  • There is no human pharmacokinetic or half-life data for the routes most widely discussed[9].
  • No direct receptor has been identified, and it is unclear how the blood-vessel, nitric oxide and growth hormone receptor findings fit together.

Regulatory Status

Not FDA-approved for any use. The FDA placed BPC-157 in compounding Category 2 ("significant safety risks") in 2023[11]; it was removed from that list in April 2026 after its nomination was withdrawn[10]. The FDA's Pharmacy Compounding Advisory Committee reviewed it in July 2026, where FDA's own briefing weighed against adding it to the compounding bulks list[9,12]. A final FDA decision had not been posted at last review.

Related Compounds

TB-500GHK-CuKPV
References (13)
  1. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495. PMID: 40756949
  2. Józwiak M, Bauer M, Kamysz W, et al. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. Pharmaceuticals (Basel). 2025;18(2):185. PMID: 40005999
  3. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13.
  4. Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PMID: 21030672
  5. Chang CH, Tsai WC, Hsu YH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. DOI: 10.3390/molecules191119066
  6. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PMID: 27847966
  7. Staresinić M, Sebečić B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. DOI: 10.1016/S0736-0266(03)00110-4
  8. Biçer O, Adanir O, Gülerýüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. DOI: 10.52312/jdrs.2026.2951
  9. U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee: BPC-157 (free base) and BPC-157 acetate. July 2026. fda.gov
  10. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (updated April 22, 2026). fda.gov
  11. Alliance for Pharmacy Compounding. 503A Categories Update for September 2023 (summarizing FDA Category 2 additions of September 29, 2023). a4pc.org
  12. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov
  13. World Anti-Doping Agency. 2022 Prohibited List, Section S0 Non-Approved Substances (effective January 1, 2022). wada-ama.org

Sources last reviewed October 2026.

D
Evidence grade D · Animal onlyWhat this means

FDA's 2026 review found no human studies, pharmacokinetic data or case reports for the TB-500 fragment itself, and the limited efficacy evidence comes from animals[1].

A seven-amino-acid lab-made piece of the repair protein thymosin beta-4, popular for injury recovery, but studied only in animals and cell dishes, never in a human trial.

Overview

TB-500 is a synthetic peptide built from residues 17 to 23 of thymosin beta-4, a 43-amino-acid protein found in nearly every human cell. Its sequence is Ac-LKKTETQ: seven amino acids with an acetyl cap on the front end[1]. That stretch is the part of thymosin beta-4 that grips actin, the protein cells use to change shape and move. FDA states plainly that TB-500 and thymosin beta-4 are not the same substance[1].

This distinction matters because most of the research people quote for TB-500 was done on full thymosin beta-4. That includes animal wound studies[7] and RegeneRx's human trials of thymosin beta-4 eye drops[8]. When FDA reviewed TB-500 in 2026, it found no human data for the fragment at all, and it recommended against allowing pharmacies to compound it[1].

One key cut from a big key ringThymosin beta-4 is like a key ring with several keys, each opening a different door: cell movement, new blood vessels, calming inflammation. TB-500 is a copy of just one key, the one that fits actin. Whether that single key can open the same doors as the full ring has barely been tested, and never in people.

Mechanism of Action

Thymosin beta-4 binds single actin units (G-actin) inside cells, holding them in reserve and controlling how quickly cells can build the filaments they need to crawl, divide and close a wound[7]. The binding happens largely through the central LKKTETQ motif, which is why that segment was chosen for TB-500[1]. In rat skin wounds, full thymosin beta-4 applied to the skin or injected sped closure of the wound surface and contraction of the wound[7], and it promotes cell migration and new blood vessel growth in experimental settings[7].

TB-500 keeps only this actin-binding motif and none of the rest of the parent protein, so effects that depend on other regions may not carry over. Its own pharmacology is thin. In horses given TB-500 under the skin, blood levels peaked within 1 to 2 hours and became unmeasurable by 6 to 10 hours[1]. In a 2024 cell experiment, the intact fragment did not speed scratch-wound closure in fibroblasts, while one of its breakdown products (Ac-LKKTE) produced a small but significant effect[1]. How, or whether, the fragment acts as a repair signal in the body is not established.

What the Research Shows

Human studies
  • TB-500 itself: no human clinical trials, human pharmacokinetic studies or published case reports were identified in FDA's 2026 review. The FDA adverse event database (FAERS) had no reports; two consumer complaints involved a blended TB-500 and BPC-157 product with no safety assessment[1].
  • Full thymosin beta-4 (not TB-500), phase 3 RCT, 2023 (n=18 with neurotrophic keratopathy, a non-healing corneal wound, 4 weeks of 0.1% eye drops): complete healing at day 28 was 60% vs 12.5% on placebo, which missed statistical significance (P=0.0656); some secondary comfort and healing measures favored treatment[8].
  • These full-protein results cannot be transferred to TB-500: the molecules differ in size and composition, and FDA did not treat thymosin beta-4 data as evidence for the fragment[1].
Animal studies
  • Rats, cut and repaired Achilles tendon (n=32, 8 per group, 4 weeks): TB-500 alone was the only treatment to significantly raise load to failure versus controls (P<0.05) and improved tissue scores (Bonar P=0.016, Movin P=0.017). Adding BPC-157 gave no further benefit[6].
  • Mice, aged and diabetic wound models: a 2003 study reported that thymosin beta-4 and a synthetic peptide containing its actin-binding domain promoted skin wound repair; FDA notes the fragment work was done in aged mice, not people[1].
  • Rats, full-thickness skin wounds (full thymosin beta-4): topical or injected thymosin beta-4 increased re-epithelialization and wound contraction[7].
  • Horses, pharmacokinetics: TB-500 and its metabolites were detectable in plasma and urine after injection, work done mainly to support doping control[1].
Cell & mechanistic
  • Human fibroblasts, scratch assay (2024): intact TB-500 showed no significant difference in wound closure versus vehicle; the metabolite Ac-LKKTE produced a small significant effect[1].
What This Could Mean in Practice

At present TB-500 has a handful of animal and cell studies and a large reputation borrowed from its parent protein. One rat tendon study is encouraging[6], but rodent tendon repair often fails to predict human results, and no human trial has tested whether the fragment helps any injury[1]. Even full thymosin beta-4, which reached phase 3 testing as eye drops, has not won approval for any use[8]. Anyone reading claims about TB-500 should check whether the study actually used the fragment.

Safety & Side Effects
  • No human safety data: FDA found no acute, repeat-dose, genotoxicity, reproductive or carcinogenicity studies for TB-500[1].
  • Immunogenicity: FDA's main stated concern is that injected peptides can trigger immune reactions, a risk raised by aggregation and impurities[1].
  • Product quality: FDA found inconsistent naming and chemical formulas in the nomination, and impurities on the only certificate of analysis were uncharacterized[1].
  • Growth-promoting biology: thymosin beta-4 drives cell migration and blood vessel growth[7]; whether a fragment carries similar concerns in people with existing cancers is unstudied.
  • Products sold online as "TB-500" may contain the fragment, full thymosin beta-4 or something else; studies of doping samples were needed just to define what the name refers to[1].

Open Questions

  • Whether TB-500 does anything useful in humans has never been tested in a trial of any size.
  • Which of thymosin beta-4's effects, if any, survive in a seven-amino-acid fragment is unclear; the one cell test of the intact fragment was negative[1].
  • Long-term safety, immune responses and effects on existing tumors are unknown[1].
  • The animal tendon result comes from a single small study and has not been independently replicated[6].

Regulatory Status

Not FDA approved. TB-500 was removed from FDA's Category 2 compounding safety-risk list in April 2026 after its nomination was withdrawn; at the July 23, 2026 advisory committee meeting, members voted 8-6 to recommend adding it to the 503A bulks list, against FDA staff advice, and formal rulemaking has not been completed[1,2,3,4]. Thymosin beta-4 and its derivatives, including TB-500, are prohibited at all times by WADA[5].

Related Compounds

BPC-157The Wolverine StackThymosin Alpha-1
References (8)
  1. U.S. Food and Drug Administration. TB-500 (free base) and TB-500 acetate: FDA briefing document, Pharmacy Compounding Advisory Committee, July 23, 2026. 2026. fda.gov
  2. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. 2026. fda.gov
  3. McDermott Will & Schulte. Bulk-list bound? PCAC backs majority of peptides in two-day public meeting. July 2026. mcdermottlaw.com
  4. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026). fda.gov
  5. World Anti-Doping Agency. 2026 Prohibited List, S2 Peptide hormones, growth factors, related substances and mimetics. wada-ama.org
  6. Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. DOI: 10.52312/jdrs.2026.2951
  7. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-8. PMID: 10469335
  8. Sosne G, Kleinman HK, Springs C, et al. 0.1% RGN-259 (thymosin β4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked phase III clinical trial. Int J Mol Sci. 2023;24(1):554. DOI: 10.3390/ijms24010554

Sources last reviewed October 2026.

B
Evidence grade B · Human RCTsWhat this means

Small randomized trials exist only for topical GHK-Cu on skin (cosmetic wrinkle studies), much of the remaining human data is from conference abstracts, and injected GHK-Cu has no published human trials[1].

A natural copper-carrying tripeptide found in blood, studied for decades in skin creams with modest cosmetic results; injected use has essentially no human evidence.

Overview

GHK is a three-amino-acid peptide (glycine-histidine-lysine) that grabs copper tightly; the copper-bound form is GHK-Cu. It was first isolated from human plasma in the 1970s, where levels run about 200 ng/mL at age 20 and fall to about 80 ng/mL by age 60[1]. That age-related decline, plus lab and animal findings that GHK-Cu boosts fibroblast growth and collagen build-up in wounds[2,5], made it a staple ingredient in anti-aging skin products[1].

Two very different uses need to be kept apart. Topical GHK-Cu has a modest body of human cosmetic research, mostly 8- to 12-week face and skin studies, many reported only as conference abstracts[1]. Injected GHK-Cu, now common in wellness clinics, has no published human trials at all[1]. FDA removed injectable GHK-Cu from its compounding safety-risk list in April 2026 only because the nomination was withdrawn, and a formal review is still pending[3,4].

A delivery van for copper with a work order attachedCopper is a required tool for the enzymes that cross-link collagen and neutralize harmful oxygen molecules. GHK-Cu works like a small delivery van that carries copper to cells in a safe, bound form. Lab studies suggest the van may also carry a work order, nudging fibroblasts to build more collagen and supportive matrix.

Mechanism of Action

GHK binds copper(II) and can deliver it to cells in a bound form, which may aid copper uptake[1]. Copper is a cofactor for lysyl oxidase, which cross-links collagen and elastin, and for antioxidant enzymes such as superoxide dismutase. In cultured human skin fibroblasts, GHK-Cu shortened cell doubling time and raised production of the growth factors bFGF and VEGF, even in cells damaged by radiation[2]. In rat wound chambers it raised collagen, glycosaminoglycan and total protein content in a concentration-dependent way, with type I and III collagen gene activity increasing, while a control tripeptide had no effect[5].

Interest broadened when GHK was run through the Broad Institute's Connectivity Map, a database of gene-expression changes in cultured human cells. The authors reported that GHK shifted expression of about 31% of human genes by at least 50%, including many tied to tissue repair, antioxidant defense and DNA repair[1]. These are computational findings in cell lines, interpreted largely by GHK's discoverer, and they do not show that the same changes happen in human skin or that they translate into health effects[1].

What the Research Shows

Human studies
  • Topical, randomized double-blind trial (Badenhorst, 2016) (female volunteers, 8 weeks, sample size not stated in the review): GHK-Cu in a nano-lipid carrier reduced wrinkle volume by 55.8% and wrinkle depth by 32.8% versus the carrier alone, and wrinkle volume by 31.6% versus a Matrixyl 3000 serum[1].
  • Topical facial cream (Leyden, 2002) (n=71 women with photoaging, 12 weeks): reported improvements in skin density, thickness, laxity, clarity, fine lines and wrinkle depth; presented only as a conference abstract[1].
  • Topical eye cream (Leyden, 2002) (n=41 women, 12 weeks): reported better results than placebo and a vitamin K cream on lines, wrinkles and skin density; conference abstract only[1].
  • Topical thigh-skin pilot (1998) (12 weeks, sample size not reported): collagen production improved in 70% of women using GHK-Cu cream versus 50% with vitamin C cream and 40% with retinoic acid[1].
  • Injected GHK-Cu: no human clinical trials have been published[1].
Animal studies
  • Rats, implanted wound chambers: GHK-Cu increased dry weight, DNA, total protein, collagen and glycosaminoglycan content in a concentration-dependent manner; collagen synthesis rose about twice as much as non-collagen protein synthesis[5].
  • Rats, healthy and diabetic wounds: collagen dressings containing GHK raised wound collagen about 9-fold in healthy rats; in ischemic wounds, GHK sped healing and lowered MMP-2, MMP-9 and TNF-beta[1].
  • Rabbits, open wounds: GHK improved wound healing, alone or with laser treatment[1].
Cell & mechanistic
  • Human dermal fibroblasts, normal and irradiated: GHK-Cu shortened population-doubling time; treated irradiated cells grew at close to normal rates and made significantly more bFGF and VEGF early on[2].
  • Human cell lines, Connectivity Map: about 31% of genes changed expression by 50% or more, 59% upward and 41% downward[1].
What This Could Mean in Practice

For skin, topical GHK-Cu has small trials suggesting modest cosmetic improvements in wrinkles and skin density over 8 to 12 weeks, but many results come from conference abstracts or industry-linked work with limited detail[1]. That evidence says nothing about injection. Injected GHK-Cu skips the skin barrier, delivers copper into the bloodstream and has no published human efficacy or safety data[1]. The gene-expression findings are intriguing hypotheses, not demonstrated effects in people.

Safety & Side Effects
  • Topical: long use in cosmetics without a prominent safety signal, but no formal safety study is cited in the main review[1].
  • Injected: no published human safety data; FDA had listed injectable GHK-Cu in Category 2 before the nomination was withdrawn, and its review is pending[3,4].
  • Copper load: excess copper is toxic to the liver and other organs; how injected GHK-Cu affects copper balance, particularly in people with conditions such as Wilson disease, is unstudied.
  • Product purity and copper content of unregulated injectable products are not standardized.

Open Questions

  • No independent, adequately sized trial has confirmed the topical cosmetic results, many of which were never fully published[1].
  • Whether injected GHK-Cu does anything beneficial, or what it does to copper levels, has never been studied in humans.
  • The gene-expression claims come from cell-line databases and have not been tested in human tissue[1].
  • Long-term effects of repeated systemic exposure are unknown.

Regulatory Status

Not FDA approved as a drug; widely used as a cosmetic ingredient. In April 2026 FDA removed injectable GHK-Cu from Category 2 (safety risks) and non-injectable GHK-Cu from Category 1 after the nominations were withdrawn, leaving neither eligible for interim compounding; FDA's advisory committee is to review GHK-Cu before the end of February 2027[3,4,6]. GHK-Cu is not specifically named on the WADA Prohibited List.

Related Compounds

AHK-CuMatrixylGLOW
References (6)
  1. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520
  2. Pollard JD, Quan S, Kang T, et al. Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Arch Facial Plast Surg. 2005;7(1):27-31. DOI: 10.1001/archfaci.7.1.27
  3. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026). fda.gov
  4. McDermott Will & Schulte. Bulk-list bound? PCAC backs majority of peptides in two-day public meeting. July 2026. mcdermottlaw.com
  5. Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993;92(5):2368-76. DOI: 10.1172/JCI116842
  6. Frier Levitt. FDA to remove 12 popular peptides from the Category 2 "do not compound" list. 2026. frierlevitt.com

Sources last reviewed October 2026.

E
Evidence grade E · Cell / minimalWhat this means

The only dedicated published study of AHK-Cu used human hair follicles and dermal papilla cells grown in the lab; no animal or human trials have been published[1].

A lab-made copper tripeptide, a close cousin of GHK-Cu, marketed for hair and skin, with one published lab study on human hair follicles and no animal or human trials.

Overview

AHK-Cu is the tripeptide alanine-histidine-lysine bound to copper. It differs from the better-known GHK-Cu by a single amino acid: alanine in place of glycine at the front end[1,2]. Unlike GHK, which circulates naturally in human blood[2], AHK-Cu is mainly known as a synthetic ingredient in hair and skin products.

Its reputation rests on a 2007 Korean study in which AHK-Cu lengthened human hair follicles kept alive in culture and stimulated the growth of dermal papilla cells, the signaling cells at the base of each follicle[1]. That study has not been followed by published animal experiments or human trials. Many claims made for AHK-Cu, such as collagen building and wound healing, are borrowed from research on GHK-Cu[2,3,4].

A near-identical twin with a much thinner fileAHK-Cu and GHK-Cu are like twins who differ by one small feature. Researchers have watched GHK-Cu in creams, cells and animal wounds for decades, but AHK-Cu has been observed in essentially one lab setting. Looking alike does not guarantee acting alike in the body.

Mechanism of Action

Like GHK, AHK carries a histidine in the second position, which lets the short peptide hold a copper(II) ion and deliver it to cells[1,2]. Copper-dependent enzymes help cross-link collagen and defend against oxidative damage, and the copper tripeptide class has been reported to increase fibroblast growth and VEGF production[1,4]. In the 2007 study, AHK-Cu at very low (picomolar to nanomolar) concentrations promoted elongation of human hair follicles in organ culture and proliferation of dermal papilla cells[1].

The proposed explanation in that study centers on cell survival. In dermal papilla cells, AHK-Cu raised the ratio of the anti-apoptotic protein Bcl-2 to the pro-apoptotic protein Bax and reduced cleaved caspase-3 and cleaved PARP, markers of programmed cell death[1]. Keeping these cells alive could, in theory, prolong the growth phase of the hair cycle. However, the drop in apoptotic cells measured by flow cytometry was not statistically significant[1], and no study has confirmed the mechanism in living scalp.

What the Research Shows

Human studies
  • None published. No clinical trials of AHK-Cu for hair loss, skin aging or any other condition have been reported. The closest human data are lab cultures of donated human hair follicles[1].
Animal studies
  • No published animal studies of AHK-Cu were identified. Animal wound data for copper tripeptides come from GHK-Cu, which increased collagen and other connective tissue in rat wound chambers[3].
Cell & mechanistic
  • Human hair follicles, organ culture (2007): AHK-Cu stimulated hair follicle elongation ex vivo[1].
  • Human dermal papilla cells: AHK-Cu increased cell proliferation, raised the Bcl-2/Bax ratio and lowered cleaved caspase-3 and PARP; the reduction in apoptotic cells was not statistically significant[1].
What This Could Mean in Practice

AHK-Cu is an early-stage cosmetic ingredient with one published lab study behind it[1]. Hair follicles in a dish grow under conditions very different from a living scalp, and many compounds that lengthen cultured follicles never show benefit in people. Whether AHK-Cu creams, serums or injections change hair density or skin quality is unknown. Claims based on GHK-Cu research[2,3] should not be assumed to apply.

Safety & Side Effects
  • No human safety data: no clinical study has reported side effects, because none has been published[1].
  • No animal toxicology: no published toxicity, carcinogenicity or reproductive studies were identified.
  • Copper exposure: injected copper peptides deliver copper directly into the body; how this affects copper balance has not been studied for AHK-Cu.
  • Regulatory review: AHK-Cu does not appear on FDA's compounding safety-risk or withdrawn nomination lists, meaning FDA has not formally evaluated it[5].

Open Questions

  • The hair follicle findings come from a single 2007 lab study that has not been independently replicated[1].
  • No published research compares AHK-Cu head to head with GHK-Cu.
  • Skin penetration, stability and how long AHK-Cu persists in tissue are unreported.
  • Whether any effect on cultured follicles translates to visible hair growth in people is untested.

Regulatory Status

Not FDA approved for any use and sold mainly as a cosmetic ingredient. AHK-Cu does not appear on FDA's lists of nominated compounding substances reviewed for safety risks, and it was not among the 12 peptides whose status changed in April 2026[5,6]. It is not specifically named on the WADA Prohibited List.

Related Compounds

GHK-CuMatrixylSNAP-8
References (6)
  1. Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-9. DOI: 10.1007/BF02978833
  2. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520
  3. Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993;92(5):2368-76. DOI: 10.1172/JCI116842
  4. Pollard JD, Quan S, Kang T, et al. Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Arch Facial Plast Surg. 2005;7(1):27-31. DOI: 10.1001/archfaci.7.1.27
  5. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026). fda.gov
  6. Frier Levitt. FDA to remove 12 popular peptides from the Category 2 "do not compound" list. 2026. frierlevitt.com

Sources last reviewed October 2026.

← 01 · Incretin & Metabolic Receptor Agonists 03 · Inflammation & Immune-Modulated Repair →